Patents by Inventor Kristen Picha

Kristen Picha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EGFR and C-Met Fibronectin Type III Domain Binding Molecules
    Publication number: 20210206825
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Application
    Filed: February 12, 2021
    Publication date: July 8, 2021
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • EGFR and c-Met fibronectin type III domain binding molecules
    Patent number: 10954284
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 23, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • CYSTEINE ENGINEERED FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES
    Publication number: 20200325210
    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
    Type: Application
    Filed: April 6, 2020
    Publication date: October 15, 2020
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Shalom Goldberg, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • Cysteine engineered fibronectin type III domain binding molecules
    Patent number: 10662235
    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: May 26, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Linus Hyun, Alastair King, Steven Jacobs, Shalom Goldberg, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • Cysteine Engineered Fibronectin Type III Domain Binding Molecules
    Publication number: 20170362301
    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
    Type: Application
    Filed: June 21, 2017
    Publication date: December 21, 2017
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Linus Hyun, Alastair King, Steven Jacobs, Shalom Goldberg, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • EGFR and C-Met Fibronectin Type III Domain Binding Molecules
    Publication number: 20170305997
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 26, 2017
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • EGFR and C-Met fibronectin type III domain binding molecules
    Patent number: 9725497
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: August 8, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Anderson, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • EGFR and c-Met fibronectin type III domain binding molecules
    Patent number: 9695228
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: July 4, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Anderson Mark, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • Antibodies binding human collagen II
    Patent number: 8906649
    Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: December 9, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: John Kehoe, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler, Jennifer Lee Gardiner
  • Anti-GLP-1R antibodies and their uses
    Patent number: 8883447
    Abstract: The present invention relates to antibodies reactive with GLP-1R, and methods of making and using them.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: November 11, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: Karyn O'Neil, Kristen Picha
  • Antibodies binding human collagen II
    Publication number: 20140220634
    Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: February 6, 2013
    Publication date: August 7, 2014
    Applicant: Janssen Biotech, Inc.
    Inventors: John Kehoe, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler, Jennifer Lee Gardiner
  • Anti-GLP-1R Antibodies and Their Uses
    Publication number: 20140162316
    Abstract: The present invention relates to antibodies reactive with GLP-1R, and methods of making and using them.
    Type: Application
    Filed: February 5, 2013
    Publication date: June 12, 2014
    Applicant: Janssen Biotech, Inc.
    Inventors: Karyn O'Neil, Kristen Picha
  • EGFR AND C-MET FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES
    Publication number: 20140155326
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Application
    Filed: November 21, 2013
    Publication date: June 5, 2014
    Applicant: Janssen Biotech, Inc.
    Inventors: Anderson Mark, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • EGFR AND C-MET FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES
    Publication number: 20140155325
    Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Application
    Filed: November 20, 2013
    Publication date: June 5, 2014
    Applicant: Janssen Biotech, Inc.
    Inventors: Anderson Mark, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
  • Antibodies binding human collagen II
    Patent number: 8394378
    Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: March 12, 2013
    Assignee: Janssen Biotech, Inc.
    Inventors: John Kehoe, Jennifer Lee Gardiner, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler
  • Anti-GLP-1R antibodies and their uses
    Patent number: 8389689
    Abstract: The present invention relates to antibodies reactive with GLP-1R, and methods of making and using them.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: March 5, 2013
    Assignee: Janssen Biotech, Inc.
    Inventors: Karyn O'Neil, Kristen Picha
  • Toll Like Receptor 3 Antagonists, Methods and Uses
    Publication number: 20120189643
    Abstract: Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
    Type: Application
    Filed: March 5, 2012
    Publication date: July 26, 2012
    Inventors: Jill M. Carton, Shizhong Chen, Mark Cunningham, Anuk Das, Karen Duffy, Jill M. Giles-Komar, Theresa J. Goletz, David M. Knight, Roberta Lamb, Mouhamadou L. Mbow, Kristen Picha, Gopalan Raghunathan, Lani San Mateo, Robert T. Sarisky, Vedrana Stojanovic-Susulic, Nicole Stowell, Raymond Sweet, Shanrong Zhao
  • Antibodies Binding Human Collagen II
    Publication number: 20120108795
    Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.
    Type: Application
    Filed: September 26, 2011
    Publication date: May 3, 2012
    Inventors: John Kehoe, Jennifer Lee Gardiner, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler
  • Toll like receptor 3 antagonists, methods and uses
    Patent number: 8153583
    Abstract: Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists, and methods of making and using the foregoing are disclosed.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: April 10, 2012
    Inventors: Jill M. Carton, Shizhong Chen, Mark Cunningham, Anuk Das, Karen Duffy, Jill M. Giles-Komar, Theresa J. Goletz, David M. Knight, Roberta Lamb, Mouhamadou L. Mbow, Kristen Picha, Gopalan Raghunathan, Lani San Mateo, Robert T. Sarisky, Vedrana Stojanovic-Susulic, Nicole Stowell, Raymond Sweet, Shanrong Zhao
  • HUMAN EPO MIMETIC HINGE CORE MIMETIBODIES, COMPOSITIONS, METHODS AND USES FOR PREVENTING OR TREATING GLUCOSE INTOLERANCE RELATED CONDITIONS OR RENAL DISEASE ASSOCIATED ANEMIA
    Publication number: 20120082669
    Abstract: The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, and methods of making and using thereof, for preventing or treating glucose intolerance and/or renal disease associated anemia, including therapeutic compositions, methods and devices.
    Type: Application
    Filed: December 6, 2011
    Publication date: April 5, 2012
    Inventors: Ian E. James, Kristen Picha